The Novusyn Research compound directory is an A–Z reference of peptides under active research or therapeutic development. Each entry summarises the mechanism of action, the trials and published literature, the regulatory status, and the editorial coverage we have published on the compound. Entries are neutral and evidence-led; no claims of efficacy or safety are made outside what regulators and the peer-reviewed literature support.
Active compound files include Semaglutide (GLP-1 receptor agonist, STEP and SUSTAIN programs), Tirzepatide (GIP/GLP-1 dual agonist, SURPASS and SURMOUNT programs), retatrutide (GIP/GLP-1/glucagon triple agonist, TRIUMPH program), orforglipron (oral non-peptide GLP-1 agonist), CagriSema (cagrilintide + semaglutide), BPC-157, TB-500, GHK-Cu, Epitalon, and the broader Khavinson bioregulator family. See also the clinical trials tracker and news.